CA3174685A1 - Proteines de fusion du coronavirus immunogeniques et methodes connexes - Google Patents

Proteines de fusion du coronavirus immunogeniques et methodes connexes Download PDF

Info

Publication number
CA3174685A1
CA3174685A1 CA3174685A CA3174685A CA3174685A1 CA 3174685 A1 CA3174685 A1 CA 3174685A1 CA 3174685 A CA3174685 A CA 3174685A CA 3174685 A CA3174685 A CA 3174685A CA 3174685 A1 CA3174685 A1 CA 3174685A1
Authority
CA
Canada
Prior art keywords
seq
cov
sars
spike
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174685A
Other languages
English (en)
Inventor
Abigail E. POWELL
Payton Anders-Benner WEIDENBACHER
Natalia FRIEDLAND
Mrinmoy SANYAL
Shaogeng Tang
Peter S. Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Board Of Trustees Of Leland Standford Junios University
Chan Zuckerberg Biohub Inc
Original Assignee
Board Of Trustees Of Leland Standford Junios University
Chan Zuckerberg Biohub Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Trustees Of Leland Standford Junios University, Chan Zuckerberg Biohub Inc filed Critical Board Of Trustees Of Leland Standford Junios University
Priority to CA3174685A priority Critical patent/CA3174685A1/fr
Publication of CA3174685A1 publication Critical patent/CA3174685A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
CA3174685A 2022-09-14 2022-09-14 Proteines de fusion du coronavirus immunogeniques et methodes connexes Pending CA3174685A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3174685A CA3174685A1 (fr) 2022-09-14 2022-09-14 Proteines de fusion du coronavirus immunogeniques et methodes connexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3174685A CA3174685A1 (fr) 2022-09-14 2022-09-14 Proteines de fusion du coronavirus immunogeniques et methodes connexes

Publications (1)

Publication Number Publication Date
CA3174685A1 true CA3174685A1 (fr) 2024-03-14

Family

ID=90230730

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174685A Pending CA3174685A1 (fr) 2022-09-14 2022-09-14 Proteines de fusion du coronavirus immunogeniques et methodes connexes

Country Status (1)

Country Link
CA (1) CA3174685A1 (fr)

Similar Documents

Publication Publication Date Title
US11939356B2 (en) Self-assembling insect ferritin nanoparticles
CN111375055B (zh) 一种2019-nCoV亚单位疫苗组合物及其免疫方法
US10744199B2 (en) Epstein-Barr virus vaccines
US20040006001A1 (en) Ferritin fusion proteins for use in vaccines and other applications
JP2023522597A (ja) Ｃｏｖｉｄ－１９に対する抗原特異的免疫療法、融合タンパク質、およびその使用方法
AU2021248665A1 (en) Binding proteins useful against ACE2-targeted viruses
US20230399364A1 (en) Immunogenic Coronavirus Fusion Proteins and Related Methods
KR20220010478A (ko) 기도 감염의 치료 또는 예방용 서브유닛 백신
WO2019092002A1 (fr) Compositions pharmaceutiques pour le traitement ou la prévention des infections virales
WO2023051701A1 (fr) Arnm, protéine et vaccin contre l'infection par sars-cov-2
CA3152665A1 (fr) Polypeptides tff2 modifies
WO2021262672A1 (fr) Constructions de rbd contre le sars-cov-2
US20230256082A1 (en) Vaccine against human-pathogenic coronaviruses
CA2914555A1 (fr) Presentation d'anticorps a un seul domaine
CA3174685A1 (fr) Proteines de fusion du coronavirus immunogeniques et methodes connexes
WO2021235503A1 (fr) Monomère protéique conjugué supportant la protéine du coronavirus, agrégat desdits monomères, et composant vaccinal comprenant ledit agrégat comme principe actif
WO2024059149A2 (fr) Protéines de fusion de coronavirus immunogènes et méthodes associées
CN107207614B (zh) 嵌合蛋白
JP2024502783A (ja) コロナウイルスワクチン
CN116964104A (zh) 免疫原性冠状病毒融合蛋白及相关方法
US11028132B1 (en) Half-life optimized linker composition
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
WO2022100703A1 (fr) Protéine membranaire modifiée du virus de l'immunodéficience humaine et son utilisation
WO2023064631A1 (fr) Ingénierie de liaison d'antigène à, et orientation sur, des adjuvants pour des réponses humorales améliorées et une immunofocalisation
Bosch-Camós et al. Nanoparticle-Based Secretory Granules Induce a Specific and Long-Lasting Immune Response through Prolonged Antigen Release